| |
In silico trials are emerging as an alternative to randomized controlled trials for rare diseases, particularly where no standard of care exists, or placebo is unethical. Download our whitepaper to learn more about this transformative approach.
|
|
Today’s Big NewsNov 15, 2024 |
| By Nick Paul Taylor Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an offer and said it is analyzing the proposal before deciding on the next steps. |
|
|
|
By Nick Paul Taylor Boston Pharmaceuticals has linked its metabolic dysfunction-associated steatohepatitis prospect to improved outcomes in a midphase trial, positioning the biotech to advance the ex-Novartis candidate toward late-stage development in 2025. |
By Fraiser Kansteiner Gilead will lay off 72 staffers in Seattle, the company confirmed Thursday. Gilead’s lone Seattle office, which the company is also closing down, focuses on “supporting research and clinical development," according to Gilead's website. |
Sponsored by IO Biotech Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform the cancer treatment landscape. |
|
Experience how our CMC and regulatory capabilities help achieve seamless, timely launches. Give your molecule the best chance of success. Start today.
|
|
By Gabrielle Masson,Darren Incorvaia,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By James Waldron Omega Therapeutics is halting work on its only clinical-stage candidate as part of a strategic refocus centered on three preclinical epigenomic controller programs including a collaboration with Novo Nordisk. |
By Zoey Becker Trump's appointment follows his pre-election promise to allow Robert F. Kennedy Jr. to "go wild" on the issue of health and medicines. |
By Darren Incorvaia,Zoey Becker Two industry veterans are taking the reins at Apriori Bio and Valo Health, biotechs backed by VC firm Flagship Pioneering. Craig Williams has been promoted to CEO-partner at Flagship and is now CEO of Apriori Bio, while Brian Alexander, M.D., is joining as CEO-partner and will lead Valo Health. |
By James Waldron After seeing success with the acquisition of Yellow Jersey Therapeutics by Johnson & Johnson this year, Kaken Pharmaceutical and Numab Therapeutics have signed another inflammation-focused collaboration. |
By Ayla Ellison,Darren Incorvaia This week on "The Top Line," we explore a neuroscientist's alleged misconduct and its impact on the future of neurodegenerative disease research. |
By Darren Incorvaia Gene therapy for some diseases, including Duchenne muscular dystrophy, can be tricky because the needed gene is often too large to fit inside the viral vector used for delivery. Researchers at the University of Rochester have now taken advantage of a basic cell biology discovery to deliver therapeutic muscular-dystrophy-related genes to mouse cells in two pieces, which the cells can then stitch together into a functional gene. |
By Angus Liu Upon reexamination, the EMA has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. But the recommendation for approval has a restriction. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we explore a neuroscientist's alleged misconduct and its impact on the future of neurodegenerative disease research. |
|
|---|
|
|
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| WhitepaperExplore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
| WhitepaperThis e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
| WhitepaperUnlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
| WhitepaperDiscover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
